For patients and their families during cancer treatment, various resources and temporary housing options aim to ease the ...

A longitudinal assessment of patient-reported outcomes demonstrated that pexidartinib (Turalio) continues to offer clinically meaningful symptom relief with extended use in patients with tenosynovial ...

Enhertu (fam-trastuzumab deruxtecan-nxki) is currently indicated as a second-line therapy for HER2-positive metastatic breast cancer.

Patients who continued to receive pembrolizumab-based therapy after disease progression had longer overall survival than patients who stopped receiving pembrolizumab-based therapy.

Researchers sought to determine whether MSD HSCT or auto-HSCT would have advantages over chemotherapy in post-remission treatment for patients with AML.

“AI can enhance clinical decision-making for common acute symptoms in a virtual urgent care setting,” the authors write. “Thoughtful integration of AI into clinical practice, combining its strengths ...